Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Oct 7, 2012; 18(37): 5219-5224
Published online Oct 7, 2012. doi: 10.3748/wjg.v18.i37.5219
Published online Oct 7, 2012. doi: 10.3748/wjg.v18.i37.5219
Table 1 Characteristics of study patients n (%)
| Gender (female %) | 10 (67) |
| Median age (yr) | 33 |
| Time of evolution to adalimumab therapy (mo) | 69 |
| Location | |
| L1 | 7 (47) |
| L2 | 1 (6) |
| L3 | 7 (47) |
| Behavior (%) | |
| Inflammatory | 10 (67) |
| Stricturing | 4 (27) |
| Fistulizing | 1 (6) |
| Perianal disease | 4 (27) |
| Smoking habit | 3 (21) |
| Previous surgical resection | 7 (47) |
| Concomitant immunosuppressants | 11 (71) |
| Reason for discontinuation of adalimumab | |
| Partial response | 7 (47) |
| Loss of efficacy | 5 (33) |
| Adverse events | 3 (20) |
- Citation: Chaparro M, Andreu M, Barreiro-de Acosta M, García-Planella E, Ricart E, Domènech E, Esteve M, Merino O, Nos P, Peñalva M, Gisbert JP. Effectiveness of infliximab after adalimumab failure in Crohn's disease. World J Gastroenterol 2012; 18(37): 5219-5224
- URL: https://www.wjgnet.com/1007-9327/full/v18/i37/5219.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i37.5219